Michael Okunewitch
Stock Analyst at Maxim Group
(0.15)
# 4,103
Out of 4,784 analysts
22
Total ratings
9.52%
Success rate
-24.39%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMMB Chemomab Therapeutics | Maintains: Buy | $4 → $7 | $1.13 | +519.47% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $3.58 | +291.06% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $0.49 | +512.24% | 1 | Jan 10, 2025 | |
| CTOR Citius Oncology | Initiates: Buy | $3 | $0.67 | +351.13% | 1 | Nov 27, 2024 | |
| OCGN Ocugen | Initiates: Buy | $4 | $0.80 | +400.31% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.95 | +1,163.16% | 1 | Sep 24, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $1.58 | +279.75% | 2 | Aug 27, 2024 | |
| LEXX Lexaria Bioscience | Maintains: Buy | $3 → $12 | $1.72 | +597.67% | 2 | Mar 5, 2024 | |
| ACRV Acrivon Therapeutics | Initiates: Buy | $24 | $2.24 | +971.43% | 1 | Oct 5, 2023 | |
| ANEB Anebulo Pharmaceuticals | Initiates: Buy | $6 | $1.36 | +341.18% | 1 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $3.08 | +484.42% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $1.06 | +21,126.42% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $15.95 | +56.74% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.81 | +231.49% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $4 | $0.30 | +1,233.33% | 1 | Mar 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.47 | +1,600.68% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $1.55 | +6,351.61% | 1 | Nov 30, 2021 |
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $4 → $7
Current: $1.13
Upside: +519.47%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $3.58
Upside: +291.06%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $0.49
Upside: +512.24%
Citius Oncology
Nov 27, 2024
Initiates: Buy
Price Target: $3
Current: $0.67
Upside: +351.13%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $0.80
Upside: +400.31%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.95
Upside: +1,163.16%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $1.58
Upside: +279.75%
Lexaria Bioscience
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $1.72
Upside: +597.67%
Acrivon Therapeutics
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $2.24
Upside: +971.43%
Anebulo Pharmaceuticals
Sep 21, 2023
Initiates: Buy
Price Target: $6
Current: $1.36
Upside: +341.18%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $3.08
Upside: +484.42%
Apr 12, 2023
Initiates: Buy
Price Target: $225
Current: $1.06
Upside: +21,126.42%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $15.95
Upside: +56.74%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.81
Upside: +231.49%
Mar 24, 2022
Initiates: Buy
Price Target: $4
Current: $0.30
Upside: +1,233.33%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $1.47
Upside: +1,600.68%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $1.55
Upside: +6,351.61%